Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2020-12-10 Director's Dealing
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2020-12-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-12-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-12-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-12-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-12-10 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 15, 2020, by Akero Therapeutics, Inc. It specifically mentions that it includes a corporate slide presentation as Exhibit 99.1, which is described as a presentation to the investment community at various conferences. The text states that the presentation is being filed as an exhibit and is incorporated by reference. There is no detailed financial data or comprehensive report content, only a presentation. According to the filing definitions, a detailed presentation for investors focusing on financials, strategy, and market position corresponds to an Investor Presentation (IP). The document length is 3468 characters, which is relatively short but contains the actual presentation as an exhibit, not just an announcement of a report. Therefore, the correct classification is Investor Presentation (IP).
2020-11-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.